A Phase 1/2 Dose-Escalation Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Hormone Receptor-Positive and HER2-Negative Breast Cancer Refractory to a Nonsteroidal Aromatase Inhibitor.
Phase of Trial: Phase I/II
Latest Information Update: 04 Apr 2016
At a glance
- Drugs Pilaralisib (Primary) ; Voxtalisib (Primary) ; Letrozole
- Indications Advanced breast cancer; Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jan 2013 Status changed from recruiting, to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 11 Jan 2013 Planned number of patients changed from 124 to 99 as reported by ClinicalTrials.gov